article · Zagazig University Medical Journal
Background: Fatty liver is the most prevalent chronic liver disease. The progressive form of fatty liver disease is non-alcholic steatohepatitis (NASH), which can lead to liver fibrosis and cirrhosis. Silymarin is a traditional liver treatment while, MSCs-CM is a new hope for treatment of chronic liver diseases. Aim of the work: To evaluate the effect of MSCs-CM versus silymarin on experimentally induced fatty liver in adult male albino rats. Material & Method: Fifty four adult male albino rats were divided into four groups: I (control group 27 rats) divided into 3 subgroups: (Subgroup Ia, Ib and Ic), II (FL group), III (FL-silymarin) and IV (FL-MSC-CM). Blood samples were collected for lipid profile. Liver tissue was prepared for H&E staining, Mallory's trichrome staining, osmic acid staining, immunohistochemical staining for alpha smooth muscle actin and caspase 3 and electron microscope examination. Statistical and morphometrical studies were performed. Results: Regarding lipid profile, α-SMA and caspase-3 the highest mean values were observed in group II while the least in group IV.H&E-stained sections of group II showed degenerated hepatocytes with vacuolated cytoplasm and darkly stained nuclei. Ultra structurally, group II revealed , rarified cytoplasm with swollen mitochondria and bundles of collagen while in group III showed some improvement, group IV most of hepatocytes appeared normal. Conclusion: MSCs-CM has a more ameliorative effect than silymarin on induced non alcoholic fatty liver disease through its antiapoptotic and anti-inflammatory effects.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/zumj.2024.280708.3301
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.